School of Chinese Medicine,
The University of Hong Kong
School of Chinese Medicine, The University of Hong Kong
Chinese Medicine, COVID-19, evidence-based medicine
Coronavirus disease 2019 (COVID-19) is an ongoing public health concern globally. This study aims to collect evidence for Chinese medicine (CM) against COVID-19 by reviewing clinical trials. We searched eleven databases. An initial search of 4,180 studies was found and the final number of included studies remained at 52. The RoB 2.0, ROBINS-I and GRADE tools were used to assess the risk of bias and level of evidence. The findings with moderate certainty in GRADE showed that compared with routine treatment (RT), Lianhua Qingwen granules (LHQW), Qingfei Paidu decoction (QFPD), Feiyan Yihao formula (FYYH), and Jinhua Qinggan granules (JHQG) have adjunctive effects on COVID-19 symptoms, including clinical efficacy rate, febrile score/time, duration of hospital stay and negative conversion time of the nucleic acid test. No serious adverse events were observed. The current evidence supported that CM formulations, particularly LHQW, QFPD, FYYH, and JHQG, have an adjuvant effect on standard treatment of COVID-19 .
Guo J, Qin Z, Lau NC, Fong TL, Meng W, Zhang ZJ, Luo Y, Wong VCT, Feng Y, Chen H. Chinese Medicine for Coronavirus Disease 2019 (COVID-19): A GRADE-Assessed Systematic Review and Meta-Analysis. Am J Chin Med. 2022;50(1):1-31. doi: 10.1142/S0192415X2250001X. Epub 2021 Dec 2. PMID: 34931587.
Conflict of Interests:
The author reports no conflicts of interest related to this study.
Dr. Haiyong Chen is an Assistant Professor and a registered Chinese Medicine Practitioner in the School of Chinese Medicine, the University of Hong Kong. He graduated from Baptist University of Hong Kong School of Chinese Medicine in 2005, obtained his MPhil in HKU School of Chinese Medicine in 2008, and PhD degree in the Chinese University of Hong Kong Faculty of Medicine in 2012.
He has diverse research interests. His current studies focus on the evaluation of effectiveness of Chinese Medicine for common diseases via evidence based approaches. He is also studying the molecular mechanisms of acute and chronic kidney diseases. He has actively published over 70 peer-reviewed papers.